IR@PKUHSC  > 北京大学第三临床医学院  > 普通外科
学科主题临床医学
HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience
Yuan, Chun-Hui; Xiu, Dian-Rong; Jiang, Bin; Li, Zhi-Fei; Li, Lei; Song, Shi-Bing; Zhang, Tong-Lin
关键词hepatitis B virus recurrence lamivudine hepatitis B immunoglobulin liver transplantation
刊名HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
2013-04-15
DOI10.1016/S1499-3872(13)60024-7
12期:2页:149-153
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]HEPATITIS-B-VIRUS ; SINGLE-CENTER EXPERIENCE ; INFECTION ; PREVENTION ; IMMUNOGLOBULIN ; PROPHYLAXIS ; OUTCOMES ; IMMUNOPROPHYLAXIS ; RESISTANCE ; EFFICACY
英文摘要

BACKGROUND: Lamivudine and hepatitis B immunoglobulin (HBIG) are widely used to treat patients with hepatitis B recurrence after liver transplantation. However, the outcomes are inconclusive. The present study was undertaken to evaluate the effect of combined therapy on patients with hepatitis B recurrence after liver transplantation.

METHODS: Twenty-two patients with hepatitis B recurrence after liver transplantation from August 2000 to October 2011 were enrolled in this study. Of these patients, 16 received lamivudine plus HBIG (combination therapy group) and 6 were treated with lamivudine alone (lamivudine-treated group). The clinical features were matched in the two groups. HBV recurrence parameters, HBsAg clearance rate, patient survival rate, and survival time were compared.

RESULTS: The average time of follow-up was 47.2 months (range 13-99). Significant difference was noted in the HBsAg clearance rate in the lamivudine-treated and combination therapy groups (50% vs 93.8%, P<0.05). There was no significant difference in the time of HBV recurrence, patient survival rate and survival time between lamivudine-treated and combination therapy groups (P>0.05).

CONCLUSION: Compared with lamivudine monotherapy, combination therapy significantly increased the HBsAg clearance rate in patients with HBV recurrence after liver transplantation. (Hepatobiliary Pancreat Dis Int 2013;12:149-153)

语种英语
WOS记录号WOS:000317438900005
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64119
专题北京大学第三临床医学院_普通外科
北京大学药学院_药事管理与临床药学系
作者单位Peking Univ, Hosp 3, Dept Gen Surg, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Yuan, Chun-Hui,Xiu, Dian-Rong,Jiang, Bin,et al. HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience[J]. HEPATOBILIARY &amp; PANCREATIC DISEASES INTERNATIONAL,2013,12(2):149-153.
APA Yuan, Chun-Hui.,Xiu, Dian-Rong.,Jiang, Bin.,Li, Zhi-Fei.,Li, Lei.,...&Zhang, Tong-Lin.(2013).HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience.HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL,12(2),149-153.
MLA Yuan, Chun-Hui,et al."HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience".HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL 12.2(2013):149-153.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yuan, Chun-Hui]的文章
[Xiu, Dian-Rong]的文章
[Jiang, Bin]的文章
百度学术
百度学术中相似的文章
[Yuan, Chun-Hui]的文章
[Xiu, Dian-Rong]的文章
[Jiang, Bin]的文章
必应学术
必应学术中相似的文章
[Yuan, Chun-Hui]的文章
[Xiu, Dian-Rong]的文章
[Jiang, Bin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。